by Daniel Schwartz | Apr 4, 2026 | Clinical Trials
Access to Care SGLT2 Inhibitors at Low GFR: Are We Drawing the Line in the Wrong Place? The SGLT2 inhibitors have had a profound effect on chronic disease management, in particular, in those living with chronic kidney disease, heart failure, or seeking to reduce...
by Daniel Schwartz | Jul 24, 2025 | Health Policy
Access to Care PharmaCare in BC: Bridging the Gaps in Prescription Coverage Medication coverage in British Columbia is meant to ensure everyone can get the drugs they need. Yet, in my experience, many patients still face barriers. In this post, I’ll...
by Daniel Schwartz | Sep 25, 2023 | Guidance for Patients, PHSP
Access to Care Reducing the Cost of Pharmaceuticals in Canada Canada is well-known for its universal healthcare system, which provides all citizens and permanent residents with access to medically necessary hospital and physician services without direct charges at the...
by Daniel Schwartz | Dec 14, 2022 | Guidance for Patients
CLINICAL TRIALS TIPS for STARTING AN SGLT2 inhibitor SGLT2i inhibitors (eg empagliflozin, dapagliflozin, canagliflozin) have a phenomenal evidence base and have been shown to be beneficial in diabetes, heart disease (particularly heart failure) and kidney disease....
by Daniel Schwartz | Dec 10, 2022 | Healthcare IT
HEALTHCARE IT 10 Opportunities to increase access to physicians through IT efficiencies In Canada (and elsewhere) we are facing unprecedented barriers in accessing physicians (both primary care & specialty care) & other healthcare providers. Many barriers...
Recent Comments